SomaLogic (SomaLogic) Cash-to-Debt : 164.25 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SomaLogic's cash to debt ratio for the quarter that ended in Sep. 2023 was 164.25.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, SomaLogic could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for SomaLogic's Cash-to-Debt or its related term are showing as below:

SLGC' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.59 Med: No Debt Max: No Debt
Current: 164.25

During the past 3 years, SomaLogic's highest Cash to Debt Ratio was No Debt. The lowest was 5.59. And the median was No Debt.

SLGC's Cash-to-Debt is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.74 vs SLGC: 164.25

SomaLogic Cash-to-Debt Historical Data

The historical data trend for SomaLogic's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

SomaLogic Cash-to-Debt Chart

SomaLogic Annual Data

Trend

Dec20

Dec21

Dec22

Cash-to-Debt

5.59

9,965.24

217.84

SomaLogic Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial								No Debt	217.84	No Debt	No Debt	164.25

Competitive Comparison of SomaLogic's Cash-to-Debt

For the Health Information Services subindustry, SomaLogic's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SomaLogic's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where SomaLogic's Cash-to-Debt falls into.

SomaLogic Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

SomaLogic's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	539.588	/	(2.477	+	0)
	=	217.84

SomaLogic's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	453.81	/	(0	+	2.763)
	=	164.25

SomaLogic (NAS:SLGC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

SomaLogic Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of SomaLogic's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

SomaLogic (SomaLogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2945 Wilderness Place, Boulder, CO, USA, 80301

Website

https://www.somalogic.com

SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

Executives

Alison Marie Roelke	officer: Chief People Officer	900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich	officer: Interim CEO	C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez	officer: General Counsel	6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs	director	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey	director	8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson	director	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman	officer: Chief Financial Officer	C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post	director	998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis	director	13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake	director	C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi	director